Evidence map›Paper›PMID 42713141›Full record

ArticleContemporary oncology (Poznan, Poland)2026

Fibroblast growth factor receptor 1 status discordance between primary breast tumours and lymph node metastases is associated with peripheral blood circulating tumour cell burden.

Marcin Braun, Jakub Czerwiński, Julia Richert, Julia Sołek, Dominik Paprocki, Tomasz Labuk, Michał Maj, Cecilia Analia Panek, Dominika Piasecka, Joanna Zofia Chrobak-Bień and 6 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Contemporary oncology (Poznan, Poland), 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

16 authors.

Marcin Braun *Department of Pathology, Chair of Oncology, Medical University of Lodz, Lodz, Poland.
Jakub Czerwiński *Department of Pathology, Chair of Oncology, Medical University of Lodz, Lodz, Poland.
Julia RichertLaboratory of Translational Oncology, Medical University of Gdansk, Gdansk, Poland.
Julia SołekDepartment of Pathology, Chair of Oncology, Medical University of Lodz, Lodz, Poland.
Dominik PaprockiDepartment of Pathology, Chair of Oncology, Medical University of Lodz, Lodz, Poland.
Tomasz LabukDepartment of Pathology, Chair of Oncology, Medical University of Lodz, Lodz, Poland.
Michał MajBRaIn Laboratories, Medical University of Lodz, Lodz, Poland.
Cecilia Analia PanekBRaIn Laboratories, Medical University of Lodz, Lodz, Poland.
Dominika PiaseckaLaboratory of Enzymology and Molecular Oncology, Intercollegiate Faculty of Biotechnology, University of Gdansk and Medical University of Gdansk, Gdansk, Poland.
Joanna Zofia Chrobak-BieńDepartment of Conservative Nursing, Faculty of Health Sciences, Medical University of Lodz, Lodz, Poland.
Dariusz NejcDepartment of Surgical Oncology, Central Teaching Hospital of the Medical University of Lodz, Lodz, Poland.
Agnieszka Wanda Piastowska-CiesielskaBRaIn Laboratories, Medical University of Lodz, Lodz, Poland.
Radzisław KordekDepartment of Pathology, Chair of Oncology, Medical University of Lodz, Lodz, Poland.
Natalia Bednarz-KnollLaboratory of Translational Oncology, Medical University of Gdansk, Gdansk, Poland.
Rafal SadejLaboratory of Enzymology and Molecular Oncology, Intercollegiate Faculty of Biotechnology, University of Gdansk and Medical University of Gdansk, Gdansk, Poland.
Hanna RomanskaDepartment of Pathology, Chair of Oncology, Medical University of Lodz, Lodz, Poland.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Introduction: Fibroblast growth factor receptor (FGFR) signalling is implicated in breast cancer (BC) progression, but little is known about FGFR status as the disease develops. We evaluated FGFR1-4 expression changes in primary tumours (PT) and matched lymph node metastases (LNM) in the context of BC phenotype and circulating tumour cell (CTC) burden. Material and methods: Fibroblast growth factor receptor 1-4, oestrogen receptor, progesterone receptor, human epidermal growth factor receptor 2 (HER2) and Ki-67 were assessed immunohistochemically in paired PT and LNM. Circulating tumour cells were quantified by imaging flow cytometry in 67 BC patients and correlated with BC phenotype and FGFR status. Results: Switch of the BC subtype between PT and LNM was observed in 3/23 cases (13.0%). In contrast, discordance in FGFR expression occurred in 11/22 (50.0%), 5/22 (22.7%), 12/22 (54.5%), and 5/21 (23.8%) cases for FGFR1, FGFR2, FGFR3, and FGFR4, respectively; in most discordant cases, the difference reflected increased expression in LNM. Circulating tumour cells were detected in 22/67 patients (32.8%), with a median burden of 5.7 CTCs per 1 million peripheral blood mononuclear cells (interquartile ranges: 3.0-17.8). Circulating tumour cell presence was not associated with lymph node (LN) status ( Conclusions: The observed association between CTCs and FGFR1 status conversion, but not LN involvement in the context of disease progression, may reflect a previously unrecognised biological feature of FGFR1- positive cells, most likely restricted to HER2-negative breast cancer.

Indexed as

BC intrinsic subtypesbreast cancercirculating tumour cellsCTCFGFRFGFR1–4heterogeneitylymph node metastasisphenotypic switch

Identifiers

PMID42713141
PMCPMC13551315

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.